Skip to main content

Laboratory Corporation of America Holdings Value Stock - Dividend - Research Selection

Laboratory

ISIN: US50540R4092 , WKN: 895308

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women\'s health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlington, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Labcorp’s New Alzheimer’s Blood Test Might Change The Case For Investing In Labcorp Holdings (LH)

2026-02-14
In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying symptomatic patients aged 55+ who are unlikely to have amyloid pathology. This test broadens access to Alzheimer’s assessment through a simple blood draw, potentially easing specialist bottlenecks and shifting more initial evaluation into primary care. Next, we’ll examine how expanding Alzheimer’s blood...

Will Labcorp (LH) Beat Estimates Again in Its Next Earnings Report?

2026-02-11
Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for

2026-02-11
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stay Ahead of the Game With Labcorp (LH) Q4 Earnings: Wall Street's Insights on Key Metrics

2026-02-11
Besides Wall Street's top-and-bottom-line estimates for Labcorp (LH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care

2026-02-11
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment of Alzheimer's disease in the primary care setting. This launch further expands Labcorp's comprehensive portfolio of Alzheimer's disease blood tests, offering clinicians solutions across both primary and specialty care

Labcorp Announced The Nationwide Availability Of The Elecsys pTau-181 Test, The First And Only Blood Test Cleared By The FDA To Aid In The Initial Assessment Of Alzheimer's Disease In The Primary Care Setting

2026-02-11

Labcorp closes takeover of Empire City assets to fuel New York expansion

2026-02-11
The company struck three deals in New York last year as part of its push to acquire hospital and regional testing labs.

Labcorp's Q4 Earnings Preview: What's in Store for the Stock?

2026-02-10
LH heads into its Q4 earnings report with rising revenue and EPS expectations, driven by Diagnostics momentum, acquisitions and expanding test demand.

Labcorp Holdings (NYSE:LH) Has Announced A Dividend Of $0.72

2026-02-09
Labcorp Holdings Inc. ( NYSE:LH ) will pay a dividend of $0.72 on the 12th of March. This means the annual payment will...

Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

2026-02-09
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026.